Review Article
Meta-Analysis of Clinical Efficacy and Safety of Tripterygium wilfordii Polyglycosides Tablets in the Treatment of Chronic Kidney Disease
Table 7
Meta-analysis of the incidence of total adverse events.
| | Subgroup analysis | No. of studies | Weighted combination | Heterogeneity | Egger’s bias
value | Metaregression
value | | OR [95% conf. interval] | value | I2 | value |
| | Disease type | | NS | 19 | 0.537 (0.399, 0.722) | | 57.9% | | | | | RNS | 6 | 0.415 (0.248, 0.693) | | 0.0% | | | | PNS | 9 | 0.493 (0.330, 0.737) | | 14.2% | | | | MN | 1 | 1.412 (0.275, 7.257) | | — | — | — | | IgAN | 1 | 3.556 (1.095, 11.546) | | — | — | — |
| | Mode of medication | | Single drug | 4 | 0.458 (0.234, 0.899) | | 41.2% | | | | | Combined use of drugs | 32 | 0.577 (0.465, 0.716) | | 49.9% | | |
| | Course of treatment | | <6 months | 9 | 0.616 (0.422, 0.900) | | 61.1% | | | | | ≥6 months | 19 | 0.580 (0.438, 0.769) | | 51.4% | | | | ≥12 months | 7 | 0.293 (0.159, 0.540) | | 0.0% | | | | Not reported | 1 | 1.000 (0.219, 4.564) | | — | — | — | |
| | Age of the patient (year) | | 0–18 | 2 | 0.819 (0.371, 1.808) | | 91.0% | | — | | | 19–65 | 25 | 0.541 (0.418, 0.701) | | 44.5% | | | | >66 | 9 | 0.505 (0.340, 0.749) | | 24.7% | | | | Total | 36 | 0.546 (0.443, 0.673) | | 48% | | | — |
|
|
